Efficacy of an adjuvant non-face-to-face multimodal lifestyle modification program for patients with treatment-resistant major depression: A randomized controlled trial.

BACKGROUND: The high prevalence of depression is partly attributable to the poor response of patients to first-line antidepressants. Multimodal programs that promote a healthy lifestyle are successful in treating depression when used as a complementary therapy, but their medium- and long-term benefits have not been demonstrated for patients with treatment-resistant depression (TRD). The main aim of this study was to compare the effectiveness of a lifestyle modification program (LMP) with mindfulness-based cognitive therapy (MBCT) and a placebo-control (written suggestions for lifestyle changes) in Spanish patients with TRD. METHODS: This controlled clinical trial randomized 94 patients with TRD into 3 arms. The primary outcome was the Beck Depression Inventory-II (BDI-II) score at baseline, 2, 6 and 12 months. The secondary outcomes were changes in scores that evaluated quality-of-life, adherence to the Mediterranean diet, physical activity, and social support. RESULTS: Relative to the placebo group, the LMP and MBCT groups had significantly better quality of life (p = 0.017; p = 0.027), and the LMP group had significantly better adherence to the Mediterranean diet (p<0.001) and reduced use of antidepressants (p = 0.036). However, the three groups showed no significant differences in BDI-II score. LIMITATIONS: Only about half of the planned 180 patients were recruited, in part due to the COVID-19 pandemic. CONCLUSIONS: There was no evidence that the LMP treatment significantly reduced symptoms of depression relative to the other groups during the COVID-19 lockdown.

Consumo moderado de alcohol y prevención de la depresión. Una revisión crítica / Moderate alcohol consumption and depression prevention. A critical review

Introducción. Hay un claro consenso en torno a que los trastornos por uso de alcohol se asocian con una mayor incidencia y peor pronóstico de depresión, además de otros problemas médicos. Sin embargo, se está planteando que el consumo de alcohol moderado previene y mejora la evolución de algunas enfermedades crónicas, especialmente cardiovasculares. No obstante, otros investigadores sugieren que no hay un consumo seguro de alcohol debido a sus efectos globales sobre la salud (aumento del riesgo de cáncer, por ejemplo). En relación a la depresión, también hay evidencia dispar sobre el posible efecto antidepresivo del consumo moderado de alcohol. Esta revisión crítica intenta resumir dicha evidencia, así como analizar la posible influencia relativa de factores involucrados. Metodología. Se realizó una búsqueda a través de PubMedncon las siguientes palabras claves y operadores booleanos: (“light alcohol” OR “light drinking” OR “moderate alcohol” OR “moderate drinking” OR “low risk drinking” OR “low risk alcohol”) AND (depress*) NOT (dependence OR abuse). Resultados. La mayoría de los 24 estudios seleccionados fueron longitudinales. El consumo moderado de alcohol se asocia a menor sintomatología depresiva en la mayoría de los estudios. Sin embargo, estos estudios no descartan que esta asociación pueda explicarse alternativamente por importantes factores de confusión no causales (estado de salud, comportamiento prosocial, otros factores de estilo de vida relacionados, etc.). Conclusiones. No hay evidencia científica clara y consistente actual que respalde el consumo moderado de alcohol per se como factor protector frente a la depresión.(AU)

Background. There is a clear consensus that alcohol use disorders are associated with poorer outcomes concerning depression, and that drinking alcohol shouldn`t be recommended because of the risk of dependence. Until recently, literature focused almost exclusively on patients with alcohol use disorders and excludes patients with moderate alcohol use (MAU). It’s has been shown that MAU can prevent or improve the evolution of chronic diseases such as cardiovascular diseases, but several researchers have suggested that there is no safe level of alcohol drinking due to other effects on health. Nevertheless, there is some evidence regarding the antidepressant effect of moderate alcohol consumption. This critical review aims to sum up the direction and tendency of current research on the effect of MAU on depression and relate the causal or confounders factors that might explain the results. Methods. A research was carried out through PubMed with the following keywords and Boolean operators: (“light alcohol” OR “light drinking” OR “moderate alcohol” OR “moderate drinking” OR “low risk drinking” OR “low risk alcohol”) AND (depress*) NOT (dependence OR abuse). Results. Most of the 23 studies selected aim to investigate longitudinal effects. MAU prevents depressive symptoms in most studies, but it is still unclear to what extent this can be alternatively explained by neurochemical factors or other confounding factors (health status, sociability, other related lifestyle factors, etc.). Conclusion. There is currently no clear and consistent scientific evidence to support moderate alcohol consumption per se as a protective factor against depression.(AU)

Effectiveness of a healthy lifestyle promotion program as adjunctive teletherapy for treatment-resistant major depression during COVID 19 pandemic: A randomized clinical trial protocol.

INTRODUCTION: Treatment-resistant depression (TRD) has a high prevalence and can be exacerbated by poor physical health and economic hardships, which have become common stressors during the current COVID-19 pandemic. The therapeutic approaches used to treat these patients are not always available, may be not be accepted by some patients, and often require face-to-face interactions. OBJECTIVE: The main aim of this study will be to evaluate the effectiveness of an Internet-based adjuvant lifestyle-based intervention for patients with TRD. METHODS: This will be a parallel, randomized, and controlled clinical trial. A total of 180 patients with TRD will be randomly allocated (1:1:1) to 1 of 3 groups: treatment prescribed by the mental health team and written suggestions for lifestyle changes (placebo control group); treatment prescribed by the mental health team, written suggestions for lifestyle changes, and an 8-week mindfulness-based cognitive therapy program (active control group); or treatment prescribed by the mental health team, written suggestions for lifestyle changes, and an 8-week lifestyle change promotion program (intervention group). We will perform this study during the COVID-19 pandemic, and will administer interventions by teletherapy, and contact participants by telephone calls, text messages, and/or teleconferences. We will collect patient data using questionnaires administered at baseline, immediately after the intervention, and after 6 and 12 months. The primary outcome will be score on the Beck Depression Inventory-II. The secondary outcomes will be score on the Clinical Global Impressions Scale (used to quantify and track patient progress and treatment response over time) and health-related quality of life measured using the European Quality of Life-5 Dimensions Questionnaire. DISCUSSION: Patients with TRD are especially vulnerable when face-to-face psychotherapy is unavailable. The main strength of the proposed study is the novelty of the intervention to be used as an adjuvant therapy. Our results may provide guidance for treatment of patients with TRD in future situations that require lockdown measures. CLINICALTRIALS REGISTRATION NUMBER: NCT04428099.

Blood alcohol level tests in nightlife recreational settings as a preventive tool.

BACKGROUND: Getting drunk is a common practice in the nightlife context and is related to risk behaviors. One potentially preventive strategy would be to conduct breathalyzer (blood alcohol content level-BAC) tests in situ, encouraging the young people to take responsibility. The aim of this study is to evaluate the efficacy of such a measure. METHOD: A sample of 555 young people were interviewed in the most popular nightlife recreational areas in three Spanish cities. After they answered to a brief questionnaire, the breathalyzer test was done and they were then informed of the results and also informed about the results, telling them what the maximum authorized rate of alcohol in expired air was for driving. After, they were asked about their drinking intentions for the rest of the night, and if they we going to be driving. RESULTS: Only 21.6% stated that they would stop drinking or drink less, while a similar percentage (21.5%) said they would drink even more than they had intended after finding out their BAC. The logistic regression indicated that the decision to drink more or less was influenced by the BAC level, the amount they had planned to drink prior to the test and high scores on "sensation seeking." Those who decided to drive had lower BAC levels and had planned to drink less prior to the interview. CONCLUSIONS: Prevention strategies involving attempts to change behavior through informing drinkers of their own BAC are controversial, since although for some it leads to their drinking less, in other cases the young people end up drinking more than they had planned.

Alcoholemias en contextos recreativos nocturnos como sistema de prevención / Blood Alcohol Level tests in nightlife recreational settings as a preventive tool

INTRODUCCIÓN: Emborracharse es frecuente en la vida recreativa nocturna, relacionándose con comportamientos de riesgo. Una estrategia potencialmente preventiva sería realizar pruebas de alcoholemia in situ, alentando a los jóvenes a responsabilizarse. El objetivo de este estudio es evaluar la eficacia de tal medida. MÉTODO: Una muestra de 555 jóvenes fue entrevistada en zonas recreativas nocturnas populares en tres ciudades españolas. Tras responder a un cuestionario, realizaron la prueba de alcoholemia y se les informó del resultado, comentándoles cuál es la alcoholemia autorizada en España para conducir. Posteriormente se les preguntó sobre sus intenciones de beber para el resto de la noche y si pensaban conducir. RESULTADOS: Tras conocer su alcoholemia sólo el 21,6% declaró que dejaría de beber o bebería menos, mientras que un porcentaje similar (21,5%) dijeron que beberían aún más de lo previsto. La regresión logística indicó que la decisión de beber más o menos venía afectada por el nivel de alcoholemia, el alcohol que se había planeado beber previamente a la prueba así como por puntuaciones altas en "búsqueda de sensaciones". Por otro lado, las personas que deciden conducir tuvieron una menor tasa de alcoholemia y ya tenían planeado beber menos el resto de la noche antes de realizar la prueba de alcoholemia. CONCLUSIONES: La realización de pruebas de alcoholemia como método preventivo da lugar a resultados contradictorios, ya que si bien en algunos casos lleva a beber menos, en otros los jóvenes terminan bebiendo más de lo que habían planeado

BACKGROUND: Getting drunk is a common practice in the nightlife context and is related to risk behaviors. One potentially preventive strategy would be to conduct breathalyzer (blood alcohol content level-BAC) tests in situ, encouraging the young people to take responsibility. The aim of this study is to evaluate the efficacy of such a measure. METHOD: A sample of 555 young people were interviewed in the most popular nightlife recreational areas in three Spanish cities. After they answered to a brief questionnaire ,the breathalyzer test was done and they were then informed of the results and also informed about the results, telling them what the maximum authorized rate of alcohol in expired air was for driving. After, they were asked about their drinking intentions for the rest of the night, and if they we going to be driving. RESULTS: Only 21.6% stated that they would stop drinking or drink less, while a similar percentage (21.5%) said they would drink even more than they had intended after finding out their BAC. The logistic regression indicated that the decision to drink more or less was influenced by the BAC level, the amount they had planned to drink prior to the test and high scores on "sensation seeking." Those who decided to drive had lower BAC levels and had planned to drink less prior to the interview. CONCLUSIONS: Prevention strategies involving attempts to change behavior through informing drinkers of their own BAC are controversial, since although for some it leads to their drinking less, in other cases the young people end up drinking more than they had planned (AU)

Hygienic-dietary recommendations for major depression treatment: study protocol of a randomized controlled trial.

BACKGROUND: Depression is a highly prevalent and disabling mental disorder with an incidence rate which appears to be increasing in the developed world. This fact seems to be at least partially related to lifestyle factors. Some hygienic-dietary measures have shown their efficacy as a coadjuvant of standard treatment. However, their effectiveness has not yet been proved enough in usual clinical practice. METHODS: Multicenter, randomized, controlled, two arm-parallel, clinical trial involving 300 patients over 18 years old with a diagnosis of Major Depression. Major depression will be diagnosed by means of the Mini-International Neuropsychiatric Interview. The Beck Depression Inventory total score at the end of the study will constitute the main efficacy outcome. Quality of Life and Social and Health Care Services Consumption Scales will be also administered. Patients will be assessed at three different occasions: baseline, 6-month follow-up and 12-month follow-up. DISCUSSION: We expect the patients in the active lifestyle recommendations group to experience a greater improvement in their depressive symptoms and quality of life with lower socio-sanitary costs. TRIAL REGISTRATION: ISRCTN73931675.

Short-term clinical stability and lack of insight are associated with a negative attitude towards antipsychotic treatment at discharge in patients with schizophrenia and bipolar disorder.

PURPOSE: The primary aim of this study was to assess the range of attitudes towards antipsychotic treatment at hospital discharge in patients with schizophrenia and bipolar disorder. The secondary aim was to analyze the relationship between patients' attitudes and sociodemographic and clinical parameters. PATIENTS AND METHODS: A cross-sectional study with a sample of patients admitted due to acute exacerbation of schizophrenia or a manic episode was conducted. Attitude towards pharmacological treatment at discharge was assessed with the 10-item Drug Attitude Inventory (DAI-10). Logistic regression was used to determine significant variables associated with attitude to medication. RESULTS: Eighty-six patients were included in the study. The mean age was 43.1 years (standard deviation [SD] 12.1), and 55.8% were males. Twenty-six percent of the patients presented a negative attitude towards antipsychotic treatment (mean DAI-10 score of -4.7, SD 2.7). Most of them had a diagnosis of schizophrenia. Multivariate analysis showed that poor insight into illness and a greater number of previous acute episodes was significantly associated with a negative attitude towards medication at discharge (odds ratio 1.68 and 1.18, respectively). CONCLUSION: Insight and clinical stability prior to admission were related to patients' attitude towards antipsychotic treatment at hospital discharge among patients with schizophrenia and bipolar disorder. The identification of factors related to the attitude towards medication would offer an improved opportunity for clinicians to select patients eligible for prophylactic adherence-focused interventions.

Hepatitis C treatment and erotomania.

The emergence of psychosis during antiviral therapy for hepatitis C is a rare side effect poorly understood in terms of etiopathogenesis, clinical features and prognosis. Erotomania is a rare psychotic syndrome characterized by the presence of a delusion: the patient (usually a female) is loved by a specific man. We present a patient who began a clinical picture of erotomania that involved his doctor a few days after treatment of interferon and ribavirin was started. He stalked his doctor, forcing the police and the court to intervene. Nevertheless, once antipsychotic treatment was established, symptoms remitted, and the patient continued antiviral treatment successfully.

Age predicts low-frequency transcranial magnetic stimulation efficacy in major depression.

BACKGROUND: Transcranial magnetic stimulation (TMS) effectiveness in major depression has so far been studied mainly with high-frequency (>1 Hz) administration (HF-TMS). However, some available studies with low-frequency TMS (LF-TMS) have provided similar response rates to HF-TMS with better tolerance, but the evidence is mixed and controversial. METHODS: Randomized, controlled, two arm, clinical trial. 34 Major Depression patients were randomly assigned to receive 20 sessions of real or sham TMS of the right dorsolateral prefrontal cortex as adjuvant treatment to pharmacotherapy. The main stimulation parameters were 20 trains at 110% of the motor threshold for 60 s at a frequency of 1 Hz. Blinded external evaluators administered the Hamilton Depression Rating Scale. RESULTS: Both treatment groups significantly improved, although there were no statistical differences between them. In the real TMS group patients age inversely correlated with improvement of depressive symptoms at the end of the study (r=-0683 p=0.002). The percentage of decrease in scores on the Hamilton Scale was greater in subjects younger than 45 years old vs. others (41.3 +/- 22.6 vs. 15.1 +/- 15.8; t=2.8 df=16, p=0.011). These real TMS subgroups did not differ significantly in their history of previous depressive disorders, or in the refractoriness indicators of the current episode. LIMITATIONS: Small size and highly refractory sample. CONCLUSION: Only younger patients benefited from LF-rTMS as adjuvant treatment to antidepressants in this study.

Effectiveness of hygienic-dietary recommendations as enhancers of antidepressant treatment in patients with depression: study protocol of a randomized controlled trial.

BACKGROUND: In recent years some studies have been published supporting the efficacy of light exposure, physical activity, sleep control and a Mediterranean diet pattern on the improvement or prevention of depression. However, to our knowledge, there have been no studies using all these measures together as an adjuvant antidepressant strategy. METHODS: Multicenter, randomized, controlled, two arm-parallel, clinical trial. Eighty depressed patients undergoing standard antidepressant treatment will be advised to follow four additional hygienic-dietary recommendations about exercise, diet, sunlight exposure and sleep. Outcome measures will be assessed before and after the 6 month intervention period. DISCUSSION: We expect the patients in the active recommendations group to experience a greater improvement in their depressive symptoms. If so, this would be a great support for doctors who might systematically recommend these simple and costless measures, especially in primary care. TRIAL REGISTRATION: ISRCTN59506583.

Melancholic versus non-melancholic depression: differences on cognitive function. A longitudinal study protocol.

BACKGROUND: Cognitive dysfunction is common among depressed patients. However, the pattern and magnitude of impairment during episodes of major depressive disorder (MDD) through to clinical remission remains unclear. Heterogeneity of depressive patients and the lack of longitudinal studies may account for contradictory results in previous research. METHODS/DESIGN: This longitudinal study will analyze cognitive differences between CORE-defined melancholic depressed patients (n = 60) and non-melancholic depressed patients (n = 60). A comprehensive clinical and cognitive assessment will be performed at admission and after 6 months. Cognitive dysfunction in both groups will be longitudinally compared, and the persistence of cognitive impairment after clinical remission will be determined. DISCUSSION: The study of neuropsychological dysfunction and the cognitive changes through the different phases of depression arise a wide variety of difficulties. Several confounding variables must be controlled to determine if the presence of depression could be considered the only factor accounting for group differences.

Plasma homovanillic acid differences in clinical subgroups of first episode schizophrenic patients.

This study evaluates the relationship between plasma homovanillic acid (pHVA) levels, which have been used to study the role of central dopamine in schizophrenia, and the positive/negative syndrome in first episode schizophrenic patients before and after antipsychotic treatment. Forty neuroleptic-naive first episode schizophrenic patients were monitored at baseline and on days 7, 14 and 28. Clinical status was evaluated with the Scale for the Assessment of Positive Symptoms (SAPS), the Scale for the Assessment of Negative Symptoms (SANS), and the Brief Psychotic Rating Scale. Plasma HVA levels were also measured. Patients were divided into predominantly positive or negative syndrome groups by subtracting SAPS from SANS scores, at baseline. A healthy control group was also enrolled. Schizophrenic patients as a group had significantly higher pHVA levels than controls at baseline (20.50+/-11.85 vs. 13.04+/-7.22 ng/ml). Moreover, 12 predominantly negative syndrome patients had similar mean baseline pHVA levels (21.30+/-12.36 ng/ml) to those of 28 predominantly positive syndrome patients (19.40+/-11.33 ng/ml). During follow-up, there was a different evolution of pHVA levels in the predominantly positive syndrome group than in the predominantly negative syndrome group, with a significantly greater global reduction of pHVA levels in the former. Although both groups showed clinical improvement following 4 weeks of treatment with risperidone, pHVA levels at endpoint were lower (13.29+/-5.91 ng/ml) than at baseline in patients in the predominantly positive syndrome group, while among those in the predominantly negative syndrome group there was no difference in pHVA levels before and after treatment (21.02+/-13.06 ng/ml). The different pHVA level profiles observed in predominantly positive and negative syndrome first episode patients after 4 weeks of treatment with risperidone suggest that each syndrome may have a different underlying neurobiology.

Low-frequency transcranial magnetic stimulation in patients with fibromyalgia and major depression.

OBJECTIVE: To study the efficacy of low-frequency transcranial magnetic stimulation in patients with fibromyalgia and major depression. DESIGN: Twenty-eight patients were randomly assigned to receive 20 sessions of real or sham transcranial magnetic stimulation of the right dorsolateral prefrontal cortex. The main stimulation parameters were 15 trains at 110% of the motor threshold for 60 seconds at a frequency of 1 Hz. Blinded external evaluators administered the fibromyalgia scales (FibroFatigue, Likert pain) and the depression scales (Hamilton Depression Rating Scale, Clinical Global Impression) during the study. RESULTS: Both treatment groups (real and sham) improved their scores in some of the scales (FibroFatigue and Clinical Global Impression), although there were no differences between them. No improvements were observed in the Likert Pain Scale in either of the groups. CONCLUSION: With the methodology used in this study, patients with fibromyalgia and major depression who received real magnetic stimulation did not present significant differences in symptoms with respect to those who received sham magnetic stimulation.

Uso de antidepresivos en pacientes diagnosticados de trastorno depresivo mayor y trastorno adaptativo / Use of antidepressants in major depression versus adjustment disorder

Introducción: En los últimos años ha aumentado mucho el uso de antidepresivos, incluso en enfermedades con una indicación poco clara, como los trastornos adaptativos. En España se ha incrementado en un 247% entre 1985 y 1994. En la mayoría de los estudios consultados se observa un incremento del uso de inhibidores selectivos de la recaptación de serotonina a expensas fundamentalmente de los inhibidores de la monoaminooxidasa y los heterocíclicos. Aunque el uso de los antidepresivos está muy extendido, hay pocos estudios centrados en el tratamiento psicofarmacológico en la depresión menor o en el trastorno adaptativo. Es importante el balance riesgo/beneficio de éste, sobre todo por los posibles efectos nocivos a largo plazo. En los trastornos depresivos menores, incluidos los adaptativos, se ha preconizado el tratamiento psicoterapéutico. El pronóstico en estos casos no es tan favorable como parecería: alrededor del 25% desarrolla una forma de depresión más grave. Hay pocas evidencias con antidepresivos, pero parecen mostrar resultados prometedores en el tratamiento a corto-medio plazo. Material y métodos: Estudiamos el uso de antidepresivos en nuestra población en 2 grupos, uno de 91 pacientes con diagnóstico de trastorno depresivo mayor (TDM) y otro de 81 con diagnóstico de trastorno adaptativo (TA). Resultados: Detectamos datos de mejor cumplimiento en los pacientes deprimidos: el 54,5% dice no olvidar nunca el tratamiento, frente al 39,7% de los pacientes con trastorno adaptativo. La adaptación laboral es menor en el grupo de TDM, pero los pacientes con TA tienden a vivir menos con compañía. En el TDM hay antecedentes de más episodios previos. Conclusiones: Los pacientes con trastorno depresivo mayor y con trastorno adaptativo reciben un tratamiento antidepresivo similar, aunque en el primer grupo hay tendencia a ser más "agresivo"

Introduction: In the last few years, the use of antidepressants has risen substantially and has been extended to disorders in which their suitability is unclear, such as adjustment disorders. In Spain, the consumption of antidepressants increased by 247% between 1985 and 1994. Most of the studies consulted show a greater use of selective serotonin reuptake inhibitors, mainly at the expense of monoamine oxidase inhibitors and heterocyclics. Despite the widespread use of antidepressants, few studies have investigated the pharmacological treatment of minor depression or adjustment disorder (AD). The risk-benefit balance of this therapy is important, especially because of the potential harmful effects in the long term. In minor depressive disorders, including AD, psychotherapeutic treatment has been recommended. The prognosis in these patients is not as favorable as it would appear: around 25% of patients develop a more severe form of depression. There is little evidence on antidepressant agents, but these drugs appear to show promising results in short- to medium-term treatment. Material and methods: We compared the use of antidepressants in 2 groups of patients: one group (n = 91) with a diagnosis of major depression (MDD) and another (n = 81) with a diagnosis of AD. Results: Compliance was better in patients with MDD: 54.5% reported full compliance compared with 39.7% of patients with AD. Adaptation to the work environment was poorer in the group with MDD, but patients with AD had a greater tendency to live alone. A personal history of prior episodes was more common in patients with MDD. Conclusions: Patients with MDD and AD received similar antidepressant treatment, although the former tended to be more "aggressive"

High (20-Hz) and low (1-Hz) frequency transcranial magnetic stimulation as adjuvant treatment in medication-resistant depression.

Studies of repetitive transcranial magnetic stimulation (rTMS) in depression have found antidepressant effects when high frequency stimulation (HF-rTMS; >1 Hz) is applied over the left prefrontal cortex (LPF). A few studies have also reported success with low frequency stimulation (LF-rTMS) to the right prefrontal cortex (RPF). Both HF-rTMS and LF-rTMS have been reported to work better in areas with cerebral hypometabolism or hypermetabolism, respectively. Thirty medication-resistant patients with major depression were randomized into three groups. The first group received sham rTMS and the second group received active rTMS (20-Hz rTMS to the LPF and 1-Hz rTMS to the RPF). The third group, however, received active rTMS that was focused on different regions of the brain after examination with single photon emission computed tomography (20-Hz rTMS to an area of relatively low activity and 1-Hz rTMS to an area showing relatively high activation). Patients and raters were blind to the treatment condition. Comparison of the sham rTMS group with the overall group that received active rTMS revealed statistically significant changes on the Hamilton Rating Scale for Depression after 10 sessions. This study demonstrated that combined 20+1-Hz rTMS was effective, but no additional advantages were obtained by focusing rTMS on areas identified by single photon emission tomography as showing high versus low levels of functional activity.